Zanubrutinib for the Treatment of MYD88 Wild-Type Waldenström Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanubrutinib for the Treatment of MYD88 Wild-Type Waldenström Macroglobulinemia: A Substudy of the Phase 3 ASPEN Trial
Blood Adv 2020 Dec 08;4(23)6009-6018, M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, RG Owen, G Cull, S Mulligan, J Czyz, JJ Castillo, M Motta, T Siddiqi, M Gironella Mesa, M Granell Gorrochategui, D Talaulikar, PL Zinzani, E Askari, S Grosicki, A Oriol, S Rule, J Kloczko, A Tedeschi, C Buske, V Leblond, J Trotman, WY Chan, J Michel, J Schneider, Z Tan, A Cohen, J Huang, CS TamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.